Exploring Biomarkers of the Carcinogenesis of Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas

Recruiting now

Conditions studied: Intraductal Papillary Mucinous Neoplasm

In brief

This is a prospective, open large cohort study to explore biomarkers for detecting early carcinogenesis of IPMN.

Key facts

Study ID

NCT05433935

Run by

Zhejiang University

People needed

5000

Starts

2022-07-01

Expected to finish

2033-12-31

Last updated by the study team

2023-01-27

Who can join

Age: any, up to 90. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• clinically diagnosed as IPMN;
• without other malignant tumor;
• agree to sign informed consent.

You may not qualify if…

• with mental disorders which can affect cognition and cooperation;
• with serious blood diseases or taking drugs that can affect peripheral blood

Where it is running

• the First Affiliated Hospital, School of Medicine, Zhejiang University — Hangzhou, Zhejiang, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.